Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries 89Bio Inc (NQ: ETNB ) 8.330 -0.350 (-4.03%) Official Closing Price Updated: 4:15 PM EDT, Jul 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 754,437 Open 8.720 Bid (Size) 8.210 (1) Ask (Size) 9.000 (1) Prev. Close 8.680 Today's Range 8.270 - 8.980 52wk Range 6.575 - 18.30 Shares Outstanding 75,480,884 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 12, 2024 From 89bio, Inc. Via GlobeNewswire 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 14, 2024 From 89bio, Inc. Via GlobeNewswire Performance YTD -26.22% -26.22% 1 Month -0.83% -0.83% 3 Month -6.19% -6.19% 6 Month -24.89% -24.89% 1 Year -53.10% -53.10% More News Read More What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday? June 05, 2024 Via Benzinga ETNB Stock Earnings: 89bio Misses EPS for Q1 2024 May 09, 2024 Via InvestorPlace Madrigal, Akero, 89bio Tumble After Lilly's Weight-Loss Drug Tackles MASH June 05, 2024 Via Investor's Business Daily The Week Ahead: What's Next June 02, 2024 Via Talk Markets 89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress May 22, 2024 From 89bio, Inc. Via GlobeNewswire 89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis May 14, 2024 From 89bio, Inc. Via GlobeNewswire 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 10, 2024 From 89bio, Inc. Via GlobeNewswire 89bio Reports First Quarter 2024 Financial Results and Provides Corporate Update May 09, 2024 From 89bio, Inc. Via GlobeNewswire 89bio to Participate in the BofA Securities 2024 Health Care Conference May 08, 2024 From 89bio, Inc. Via GlobeNewswire 89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH May 02, 2024 From 89bio, Inc. Via GlobeNewswire 89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors April 17, 2024 From 89bio, Inc. Via GlobeNewswire 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 05, 2024 From 89bio, Inc. Via GlobeNewswire 89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis March 27, 2024 From 89bio, Inc. Via GlobeNewswire Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy? March 17, 2024 Via The Motley Fool 89bio Initiates Phase 3 ENLIGHTEN-Fibrosis Trial of Pegozafermin in Non-Cirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Fibrosis March 12, 2024 From 89bio, Inc. Via GlobeNewswire 89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) March 08, 2024 From 89bio, Inc. Via GlobeNewswire Over $20M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying March 07, 2024 Via Benzinga 89bio to Participate in the Leerink Partners Global Biopharma Conference March 05, 2024 From 89bio, Inc. Via GlobeNewswire Akero Rockets 27%, Prodding Rival 89bio Higher, On Promising Liver Disease Treatment March 04, 2024 Via Investor's Business Daily 12 Health Care Stocks Moving In Monday's Pre-Market Session March 04, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday March 04, 2024 Via InvestorPlace Why Bitdeer Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session March 04, 2024 Via Benzinga 89bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates February 29, 2024 From 89bio, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.